01—Abstract
Summary
Summary of the 10-Q filed April 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported solid top-line growth in the first quarter of 2026, with total revenues increasing by approximately 19% year-over-year to $3.61 billiona.
This growth was primarily driven by a substantial increase in collaboration revenue, largely from the Sanofi collaboration, which saw a significant uptick in Dupixent and Kevzara sales. Despite overall revenue growth, net income experienced a decline of approximately 10% to $727.2 millionb, leading to a decrease in diluted earnings per share to $6.75 from $7.27 in the prior year period. This was influenced by a significant increase in operating expenses, particularly in research and development and cost of goods sold.
The company also continued its aggressive share repurchase program and declared a quarterly dividend, indicating a focus on returning value to shareholders. Investors will be closely watching the company's efforts to navigate competitive pressures in key franchises like EYLEA and the ongoing legal matters. Regeneron's balance sheet remains robust, with total assets increasing and a healthy working capital position.
The company generated significant cash flow from operations. However, an increase in current liabilities, notably due to a significant finance lease liability, warrants attention. The company also provided updated guidance on expected capital expenditures for the full year 2026, indicating continued investment in infrastructure.
02—Key points
Key Highlights
- Total revenues increased by 19% to $3.61 billion, driven by strong collaboration revenue, mainly from Dupixent and Kevzara.
- Net income decreased by 10% to $727.2 million, with diluted EPS falling to $6.75 from $7.27.
- Operating expenses rose by approximately 20%, primarily due to higher R&D and cost of goods sold.
- EYLEA U.S. net sales declined by 36%, attributed to competitive pressures and the transition to EYLEA HD.
- The company repurchased approximately $803.2 million of its common stock during the quarter and announced a new $3.0 billion repurchase program.
- Regeneron declared a quarterly cash dividend of $0.94 per share, payable in June 2026.
- Cash and cash equivalents decreased by $155.5 million to $2.96 billion, while total marketable securities increased by $304.0 million.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed April 29, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $3.61B$3.03B | +19.0% |
| R&D Expenses | $1.54B$1.33B | +16.3% |
| SG&A Expenses | $647.70M$633.00M | +2.3% |
| Operating Expenses | $2.96B$2.44B | +21.6% |
| Operating Income | $642.90M$591.70M | +8.7% |
| Net Income | $727.20M$808.70M | −10.1% |
| EPS (Basic) | $6.99$7.58 | −7.8% |
| EPS (Diluted) | $6.75$7.27 | −7.2% |
| Shares Outstanding (Basic) | 104.00M106.70M | −2.5% |
| Shares Outstanding (Diluted) | 107.70M111.20M | −3.1% |
05—Questions
Frequently Asked Questions
What drove the revenue growth in Q1 2026?
Revenue growth was primarily driven by a significant increase in collaboration revenue, particularly from the Sanofi collaboration, which benefited from higher global sales of Dupixent and Kevzara. Total revenues increased by 19% year-over-year to $3.61 billion.
Why did net income decrease despite revenue growth?
Net income decreased by 10% to $727.2 million due to a substantial increase in operating expenses. This included higher research and development costs, cost of goods sold, and costs related to collaboration and contract manufacturing, which outpaced the revenue growth.
What is the company's strategy regarding capital allocation?
Regeneron continues to return capital to shareholders through share repurchases and dividends. The company repurchased approximately $803.2 million of its common stock in the quarter and announced a new $3.0 billion repurchase program. A quarterly cash dividend of $0.94 per share was also declared.
How is the EYLEA franchise performing, and what are the key concerns?
While EYLEA HD U.S. sales increased, overall EYLEA franchise U.S. net sales declined by 12% due to competitive pressures and the ongoing transition from EYLEA to EYLEA HD. EYLEA U.S. net sales specifically decreased by 36%. The company anticipates continued increased competition from biosimilars for EYLEA.
06—Continue